<SEC-DOCUMENT>0001193125-21-229169.txt : 20210729
<SEC-HEADER>0001193125-21-229169.hdr.sgml : 20210729
<ACCEPTANCE-DATETIME>20210729160209
ACCESSION NUMBER:		0001193125-21-229169
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210729
FILED AS OF DATE:		20210729
DATE AS OF CHANGE:		20210729

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		211127318

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d591999d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of July 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39173</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 802,
West Tower, OmniVision, 88 Shangke Road, Pudong District </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 201210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> Form <FONT
STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">I-MAB</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By :</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name :</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title :</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: July&nbsp;29, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit Index </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 99.1&#151;Press Release </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d591999dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g591999g88w32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Announces Authorization of a Renewed Stock Repurchase
Program by the Company up to US$40 Million </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHANGHAI and GAITHERSBURG, MD. &#150; July</B><B></B><B>&nbsp;29, 2021 &#150;</B> <FONT
STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of
Directors (the &#147;Board&#148;) has authorized a new stock repurchase program. With the Board&#146;s authorization, the Company may repurchase up to US$40&nbsp;million of its ordinary shares in the form of American depositary shares
(&#147;ADS&#148;) over the next 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2020, the Board first authorized a stock repurchase program under which the Company may repurchase up
to US$20&nbsp;million of its ordinary shares in the form of ADS over a <FONT STYLE="white-space:nowrap">12-month</FONT> period. The renewed stock repurchase program now has an increased cap of US$40&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased that the Board has authorized this new stock repurchase program by the Company.&#148; said Dr.&nbsp;Jingwu Zang, Founder and Chairman of <FONT
STYLE="white-space:nowrap">I-Mab,</FONT> &#147;The Company&#146;s fundamentals remain very strong and the authorization demonstrates the confidence we have in our globally competitive innovative pipeline and our journey to becoming a fully
integrated global biopharma.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repurchases, if any, under the program will be made at the discretion of management, and will depend upon market
pricing and conditions, business, legal, accounting and other considerations. Any such share purchases will be made by the Company from time to time in open market transactions, or otherwise in compliance with Rule
<FONT STYLE="white-space:nowrap">10b-18</FONT> under the Securities Exchange Act of 1934, or pursuant to a trading plan adopted in accordance with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> of the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The repurchase program is effective upon and from the date on which a formal stock repurchase plan engagement agreement is signed with a qualified
broker-dealer(s), and terminates over a twelve-month period depending upon market and economic conditions, and other factors including price, legal and regulatory requirements and capital availability. The program does not obligate <FONT
STYLE="white-space:nowrap">I-Mab</FONT> to acquire any particular number of its ADSs, and the program may be modified or suspended at any time at the management&#146;s discretion. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g591999g88w32.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon,
commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company&#146;s mission is to bring transformational medicines to patients around the world through innovation. <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> innovative pipeline of more than 10 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates is driven by the Company&#146;s
<FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(Proof-of-Concept)</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT>
development strategies through internal R&amp;D and global partnerships. The Company is on track to transition from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&amp;D capabilities,
world-class GMP manufacturing facilities and commercial capability. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has offices in Beijing, Shanghai, Hangzhou, Hong Kong and Maryland, United States. For more information, please visit <U><FONT
STYLE="white-space:nowrap">http://ir.i-mabbiopharma.com</FONT></U> and follow <FONT STYLE="white-space:nowrap">I-Mab</FONT> on <U>LinkedIn</U>, <U>Twitter</U> and <U>WeChat</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement contains forward-looking statements. These statements are made under the &#147;safe harbor&#148; provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as &#147;will,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;future,&#148; &#147;intends,&#148; &#147;plans,&#148;
&#147;believes,&#148; &#147;estimates,&#148; &#147;confident&#148; and similar statements. <FONT STYLE="white-space:nowrap">I-Mab</FONT> may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and
Exchange Commission (the &#147;SEC&#148;), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical
facts, including statements about <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause
actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to demonstrate the safety and efficacy of its drug
candidates; the clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> drug candidates; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to achieve commercial success for its drug candidates, if approved; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT>
ability to obtain and maintain protection of intellectual property for its technology and drugs; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> reliance on third parties to conduct drug development, manufacturing and other services; <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> limited operating history and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain additional funding for operations and to complete the development and commercialization of its drug
candidates; and the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s clinical development, commercial and other operations, as well as those risks more fully discussed in the &#147;Risk Factors&#148;
section in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> as well as discussions of potential risks, uncertainties, and other important factors in <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g591999g88w32.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For more information, please contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Contacts </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jielun Zhu <BR>Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">jielun.zhu@i-mabbiopharma.com</FONT></U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+86 21 6057 8000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gigi Feng <BR>Chief Communications Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">gigi.feng@i-mabbiopharma.com</FONT></U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+86 21 6057 8000</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>The Piacente Group, Inc.</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emilie Wu</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U>emilie@thepiacentegroup.com</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6039 8363</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g591999g88w32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g591999g88w32.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MZKCH]CT%6#*&4@J1D$=Z^C3OJCK%I@% !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 '2@#PK5?&,GBCQC=QQO_P 2ZV0I;*#PV&Y?ZG^0%>[A*7LX^;/G,QJ^
MU>FR'5W'D@#ANE?*YY@\3BZL52C=)>6[_I'H82K"G%\S+L>G7]Y:F>WLII8@
M<%D0FOF*F7XF@[3A^OY'IP?M8\T-48UR&C8HZE6'4$8(J8IIV9E+0S)SBNN"
M,)'5#H*\0] [KP7J[31MILQR8EW1$_W>X_"O?RS$N2]C+IL=5&=_=9UU>R=
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M7T%>Q@<LE)JI66G8VC#JSM>G KZ8V"@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * (KFUM[VV>VNH(YX)!AHY%#*P]P::;3NA-)JS.8U#P'I\X+6<C
MVK?W?OK^1Y_6N^GCYQTEJ>76RNE/6#L<W/X*UB-\0P>:OKO1?_9J[HXVDUJ[
M?>>;++:Z?NJ_W?YG:^'O#MOHD&[E[J0?/(1T]AZ"O+Q&)E6=NA[6$PD</&_5
MFL;>!I1*88S(.0Q49'XUQ.G!OF:5SLL2U8PH * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
, * "@ H * "@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
